Sanofi denies abuse of FDA’s Orange Book
Sanofi-Aventis says that Mylan Pharmaceuticals’ allegations that it illegally cornered the market for long-lasting insulin are merely a mishmash of “antitrust buzz words”.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10